AMANDA DUPLANTIS: Open Payments
NPI 1891153813 · BROUSSARD, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$623 in 41 payments from 13 companies in 2025. Trend: 2023 $566 · 2024 $551 · 2025 $623
Food & beverage: $623
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $157 |
| Axsome Therapeutics, Inc. | 4 | $84 |
| AstraZeneca Pharmaceuticals LP | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Corium, LLC | 5 | $42 |
| PFIZER INC. | 2 | $42 |
| Ardelyx, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $36 |
| Novo Nordisk Inc | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
Products named: VRAYLAR, Auvelity, AIRSUPRA, REXULTI, Azstarys, IBSRELA, NURTEC ODT, Ozempic.
Industry payments across LA — which companies pay providers there.
